Use of Autologous Serum Eyedrops for the Treatment of Ocular Surface Disease: First US Experience in a Large Population as an Insurance-Covered Benefit

Dalmon, Cyril A; Chandra, Naveen; Jeng, Bennie H.

doi:10.1001/archophthalmol.2012.1652

Cited by 18 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelet-derived products have shown an important role in the treatment of dry eye syndrome, dormant ulcers (epithelial defects of the cornea that fail to heal), ocular surface syndrome after Laser In Situ Keratomileusis (LASIK), and for surface reconstruction after corneal perforation associated also with amniotic membrane transplantation [61,[112][113][114][115]. Furthermore, platelet derivatives appear to show therapeutic effects in some diseases such as diabetic keratitis, keratocongiuntivite sicca, traumatic post-infectious and vernal ulcers that lead to a condition known as persistent epithelial defects [116].…”

Section: Ophthalmologymentioning

confidence: 99%

Platelet Derivatives in Regenerative Medicine: An Update

Pascale¹,

Sommese²,

Casamassimi³

et al. 2015

Transfusion Medicine Reviews

169

149

View full text Add to dashboard Cite

Section: Ophthalmologymentioning

confidence: 99%

Platelet Derivatives in Regenerative Medicine: An Update

Pascale¹,

Sommese²,

Casamassimi³

et al. 2015

Transfusion Medicine Reviews

169

149

View full text Add to dashboard Cite

“…With the optimized manufacturing protocol, the serum and tear concentration of TGF-β are supposed to be equivalent and dilution may not be necessitated15. Recently, several studies found that higher concentrations (50–100%) seemed to provide greater benefits without inducing detrimental effects on the corneal epithelial healing516171819202122.…”

mentioning

confidence: 99%

Undiluted Serum Eye Drops for the Treatment of Persistent Corneal Epitheilal Defects

Lekhanont

Jongkhajornpong

Anothaisintawee

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Several studies found that 50–100% serum eye drops provided greater benefits without inducing detrimental effects on the corneal epithelial healing. This study assessed the efficacy of undiluted serum eye drops for the treatment of persistent corneal epithelial defects (PED). A total of 109 eyes received 100% serum eye drops for PED were recruited into this study. The data were compared with an historical control group of 79 eyes with PED who received conventional treatments from 2006–2011 at the same institution. Main outcome measures were complete healing of PED and incidence of adverse events. No significant difference in demographics between the 2 groups was noted. The success rate of the treatment and control groups were 87.16% (95% CI 0.79–0.93) and 69.62% (95% CI 0.59–0.80) (P = 0.001), respectively. The median time to complete epithelialization was 14 days (95% CI 12–21) in the treatment group and 28 days (95% CI 21–59) in the control group (P = 0.001). Serum treatment, primary diagnosis of non-limbal stem cell deficiency etiology, and prior contact lens wear significantly correlated with the corneal re-epithelialization. There were no serious side effects encountered during the study period. In conclusion, undiluted serum therapy is effective and safe for treating PED.

show abstract

“…It has been suggested that the length of time required for healing directly correlated with the length of time a persistent epithelial defect has been present [19]. Some studies applied the serum earlier in the disease course rather than as a last resort since the patients might derive as much benefits as those who were recalcitrant to standard treatments [9, 21]. Furthermore, corneal graft re-epithelialization after corneal transplantation usually takes no longer than 1 week [22].…”

Section: Methodsmentioning

confidence: 99%

Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery

Lekhanont

Jongkhajornpong

Choubtum

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

The purpose of this study was to investigate the efficacy and safety of topical 100% serum eye drops for corneal epithelial defect after ocular surgery. A total of 181 patients who received topical 100% serum therapy for the treatment of corneal epithelial defect following several different types of ocular surgery were recruited into this study. Each patient already failed conventional medical therapy before being prescribed 100% serum eye drops. Slit-lamp biomicroscopic examination with fluorescein staining was performed at baseline and all follow-up visits. The main outcome measures were the rate of complete healing of the corneal epithelial defect and incidence of adverse events. One hundred and seventy-eight eyes (98.34%) received autologous serum eye drops, and 3 (1.66%) received allogeneic serum eye drops. The overall success rate of treating persistent postoperative epithelial defect using 100% serum eye drops was 93.92% (95% CI 0.88–0.98). The median time to complete corneal epithelialization was 4 days (95% CI 4-5). Adverse reactions were observed in 3 patients (1.66%), including sticky sensation with minimal eye discomfort and asymptomatic trace corneal subepithelial infiltration. No serious complications were reported. In conclusion, 100% serum eye drops are effective, safe, and tolerable for treating postoperative corneal epithelial defect following ocular surgeries.

show abstract

Use of Autologous Serum Eyedrops for the Treatment of Ocular Surface Disease: First US Experience in a Large Population as an Insurance-Covered Benefit

Cited by 18 publications

References 6 publications

Platelet Derivatives in Regenerative Medicine: An Update

Platelet Derivatives in Regenerative Medicine: An Update

Undiluted Serum Eye Drops for the Treatment of Persistent Corneal Epitheilal Defects

Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery

Contact Info

Product

Resources

About